Added to YB: 2025-07-09
Pitch date: 2025-07-07
FBIO [bullish]
Fortress Biotech, Inc.
-0.52%
current return
Author Info
No bio for this author
Company Info
Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally.
Market Cap
$67.7M
Pitch Price
$1.92
Price Target
N/A
Dividend
N/A
EV/EBITDA
1.59
P/E
0.62
EV/Sales
-0.49
Sector
Biotechnology
Category
special_situation
Fortress Biotech – The numbers that describe the uniqueness behind the company
FBIO: Undervalued biotech company with 6 key assets acquired for only $2.97M upfront. 2 FDA-approved drugs (EMROSI, UNLOXCYT) generating revenue. CUTX-101 has PDUFA 9/30/25 with $129M milestone potential + PRV worth ~$150M. CAEL-101 sold to AstraZeneca ($56.9M received, $124.6M potential). Dotinurad and Triplex advancing with significant upside. Fortress retains 42.7-83.4% ownership in subsidiaries + royalties.
Read full article (49 min)